Conversely, the lack of significant correlation between HER-2/neu expression and tumor grade in the present study (p = 0.747) suggests that additional factors, such as HPV status and molecular alterations, may modulate its expression and clinical implications. This evidence concerns the gene ERBB2 and neoplasm.